Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca’s (AZN) Imfinzi plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone. The trial was not statistically powered to formally test overall survival however a descriptive analysis demonstrated no detriment. The safety and tolerability of Imfinzi plus BCG induction and maintenance therapy was consistent with the known safety profiles of the individual medicines, with no new safety concerns identified. The addition ofImfinzidid not compromise patients’ ability to complete BCG induction and maintenance therapy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca call volume above normal and directionally bullish
- Pharma imports to U.S. surged in March ahead of tariffs, Reuters says
- AstraZeneca reports results from DESTINY-Breast11 trial
- NVO Earnings: Novo Nordisk Stock Rises Despite Cutting Fiscal 2025 Outlook
- FDA announces expanded use of unannounced inspections at foreign facilities